Comparison of DNA and mRNA vaccines against cancer

Jahanafrooz, Zohreh; Baradaran, Behzad; Mosafer, Jafar; Hashemzaei, Mahmoud; Rezaei, Tayebeh; Mokhtarzadeh, Ahad; Hamblin, Michael R.

doi:10.1016/j.drudis.2019.12.003

Cited by 130 publications

(123 citation statements)

References 58 publications

Supporting

Mentioning

110

Contrasting

Order By: Relevance

“…mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, short production cycles, low-cost manufacturing, and safe administration [46]. The procedures of mRNA vaccine development include the selection of antigens, the optimization of sequences, the screening of modified nucleotides, the optimization of delivery systems, the evaluation of immune response and safety test [47]. Particularly, no mRNA vaccine has yet entered the market, thus it may take more time in quality standards establishment and safety evaluation.…”

Section: Mrna Vaccinesmentioning

confidence: 99%

Progress and Prospects on Vaccine Development against SARS-CoV-2

et al. 2020

View full text Add to dashboard Cite

In December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China and other countries worldwide. So far, more than 460,000 confirmed cases were diagnosed in nearly 190 countries, causing globally over 20,000 deaths. Currently, the epidemic is still spreading and there is no effective means to prevent the infection. Vaccines are proved to be the most effective and economical means to prevent and control infectious diseases. Several countries, companies, and institutions announced their programs and progress on vaccine development against the virus. While most of the vaccines are under design and preparation, there are some that have entered efficacy evaluation in animals and initial clinical trials. This review mainly focused on the progress and our prospects on field of vaccine development against SARS-CoV-2.

show abstract

Section: Mrna Vaccinesmentioning

confidence: 99%

Progress and Prospects on Vaccine Development against SARS-CoV-2

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In addition, DNA vaccines carry a potential risk of integration into the host genome, which may result in insertional mutagenesis. In contrast, mRNA vaccines are only targeted for cytoplasmic delivery, circumventing the risk of genomic integration [4]. The relatively short half-life results in transient and more controlled expression of the encoded antigen.…”

Section: Introductionmentioning

confidence: 99%

Opportunities and Challenges in the Delivery of mRNA-Based Vaccines

et al. 2020

View full text Add to dashboard Cite

In the past few years, there has been increasing focus on the use of messenger RNA (mRNA) as a new therapeutic modality. Current clinical efforts encompassing mRNA-based drugs are directed toward infectious disease vaccines, cancer immunotherapies, therapeutic protein replacement therapies, and treatment of genetic diseases. However, challenges that impede the successful translation of these molecules into drugs are that (i) mRNA is a very large molecule, (ii) it is intrinsically unstable and prone to degradation by nucleases, and (iii) it activates the immune system. Although some of these challenges have been partially solved by means of chemical modification of the mRNA, intracellular delivery of mRNA still represents a major hurdle. The clinical translation of mRNA-based therapeutics requires delivery technologies that can ensure stabilization of mRNA under physiological conditions. Here, we (i) review opportunities and challenges in the delivery of mRNA-based therapeutics with a focus on non-viral delivery systems, (ii) present the clinical status of mRNA vaccines, and (iii) highlight perspectives on the future of this promising new type of medicine.

show abstract

“…The mRNA vaccine provides a promising alternative to conventional vaccine approaches because of its high potential, short production cycle, low production cost, and safe delivery (34). The development of an mRNA vaccine includes antigen selection, sequence optimization, screening of modified nucleotides, optimization of the delivery system, and evaluation of immune responses and safety testing (17).…”

Section: Mrna Vaccinesmentioning

confidence: 99%

Coronavirus Disease 2019 Vaccine Development: An Overview

Sumirtanurdin

Barliana

2021

Viral Immunology

View full text Add to dashboard Cite

To this day, the coronavirus disease 2019 (COVID-19) pandemic has not shown signs of abating. Moreover, the virus responsible for the pandemic, severe acute respiratory syndrome coronavirus 2, has evolved into three different variants. This phenomenon highlights an even greater need to develop drugs and vaccines to control the rate of infection and spread of the disease. As of July 7, 2020, at least 160 vaccine candidates, 21 of which have entered the clinical trial phase, have been developed. This article describes the latest advances in development, reliable platforms, strategies used, and challenges that remain in developing COVID-19 vaccines.

show abstract

Comparison of DNA and mRNA vaccines against cancer

Cited by 130 publications

References 58 publications

Progress and Prospects on Vaccine Development against SARS-CoV-2

Progress and Prospects on Vaccine Development against SARS-CoV-2

Opportunities and Challenges in the Delivery of mRNA-Based Vaccines

Coronavirus Disease 2019 Vaccine Development: An Overview

Contact Info

Product

Resources

About